CN110772480A - 苯达莫司汀药剂组合物及应用 - Google Patents
苯达莫司汀药剂组合物及应用 Download PDFInfo
- Publication number
- CN110772480A CN110772480A CN201911109940.3A CN201911109940A CN110772480A CN 110772480 A CN110772480 A CN 110772480A CN 201911109940 A CN201911109940 A CN 201911109940A CN 110772480 A CN110772480 A CN 110772480A
- Authority
- CN
- China
- Prior art keywords
- bendamustine
- pharmaceutical composition
- injection
- peg
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 229960002707 bendamustine Drugs 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 title claims abstract description 9
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 claims abstract description 31
- 229960001215 bendamustine hydrochloride Drugs 0.000 claims abstract description 30
- 239000003381 stabilizer Substances 0.000 claims abstract description 15
- 239000007924 injection Substances 0.000 claims abstract description 14
- 238000002347 injection Methods 0.000 claims abstract description 14
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 9
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 8
- 150000002148 esters Chemical class 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 239000012453 solvate Substances 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 26
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 18
- 239000012528 membrane Substances 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 235000006708 antioxidants Nutrition 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- 239000000787 lecithin Substances 0.000 claims description 6
- 229940067606 lecithin Drugs 0.000 claims description 6
- 235000010445 lecithin Nutrition 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims description 6
- 229940035024 thioglycerol Drugs 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 5
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 239000008215 water for injection Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 4
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 4
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000011821 Indolent B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 2
- 235000019136 lipoic acid Nutrition 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims description 2
- 229940001607 sodium bisulfite Drugs 0.000 claims description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 2
- 229940001482 sodium sulfite Drugs 0.000 claims description 2
- 235000010265 sodium sulphite Nutrition 0.000 claims description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 2
- 229940001474 sodium thiosulfate Drugs 0.000 claims description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 2
- 229960002663 thioctic acid Drugs 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 7
- 238000010790 dilution Methods 0.000 abstract description 4
- 239000012895 dilution Substances 0.000 abstract description 4
- 239000007788 liquid Substances 0.000 abstract description 3
- 238000013112 stability test Methods 0.000 abstract description 2
- 229940090044 injection Drugs 0.000 abstract 2
- 229940043761 bendamustine injection Drugs 0.000 abstract 1
- 239000000047 product Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000008354 sodium chloride injection Substances 0.000 description 5
- 230000001502 supplementing effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229960004641 rituximab Drugs 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 3
- XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000021023 sodium intake Nutrition 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- FGCSIJPPCNCQJB-FAOVPRGRSA-M sodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;chloride Chemical compound [Na+].[Cl-].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O FGCSIJPPCNCQJB-FAOVPRGRSA-M 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911109940.3A CN110772480B (zh) | 2016-03-25 | 2016-03-25 | 苯达莫司汀药剂组合物及应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911109940.3A CN110772480B (zh) | 2016-03-25 | 2016-03-25 | 苯达莫司汀药剂组合物及应用 |
CN201610179590.8A CN105726472B (zh) | 2016-03-25 | 2016-03-25 | 苯达莫司汀药剂组合物及应用 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610179590.8A Division CN105726472B (zh) | 2016-03-25 | 2016-03-25 | 苯达莫司汀药剂组合物及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110772480A true CN110772480A (zh) | 2020-02-11 |
CN110772480B CN110772480B (zh) | 2022-05-17 |
Family
ID=56252042
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610179590.8A Active CN105726472B (zh) | 2016-03-25 | 2016-03-25 | 苯达莫司汀药剂组合物及应用 |
CN201911109940.3A Active CN110772480B (zh) | 2016-03-25 | 2016-03-25 | 苯达莫司汀药剂组合物及应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610179590.8A Active CN105726472B (zh) | 2016-03-25 | 2016-03-25 | 苯达莫司汀药剂组合物及应用 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN105726472B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019099557A (ja) * | 2017-11-28 | 2019-06-24 | 日本化薬株式会社 | ベンダムスチンを含有する溶液製剤 |
CN110123747A (zh) * | 2019-04-26 | 2019-08-16 | 嘉兴市爵拓科技有限公司 | 苯达莫司汀的制剂 |
CN111557904A (zh) * | 2020-04-09 | 2020-08-21 | 比卡生物科技(广州)有限公司 | 苯达莫司汀组合物及其用途 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10306724A1 (de) * | 2002-02-28 | 2003-09-18 | G O T Therapeutics Gmbh | Vesikuläre Verkapselung von Bendamustin |
CN101219112A (zh) * | 2008-01-28 | 2008-07-16 | 济南帅华医药科技有限公司 | 一种含苯达莫司汀的复方抗癌缓释注射剂 |
CN101584668A (zh) * | 2009-06-19 | 2009-11-25 | 江苏奥赛康药业有限公司 | 盐酸苯达莫司汀冻干粉针剂 |
CN102164579A (zh) * | 2008-09-25 | 2011-08-24 | 赛福伦公司 | 苯达莫司汀的液体配制品 |
CN102413816A (zh) * | 2009-04-28 | 2012-04-11 | 赛福伦公司 | 苯达莫司汀的口服制剂 |
CN103989641A (zh) * | 2014-05-29 | 2014-08-20 | 四川汇宇制药有限公司 | 一种注射用盐酸苯达莫司汀组合物的制备方法 |
CN104203235A (zh) * | 2012-02-14 | 2014-12-10 | 鹰制药股份有限公司 | 苯达莫司汀的制剂 |
CN104302291A (zh) * | 2012-03-20 | 2015-01-21 | 鹰制药股份有限公司 | 苯达莫司汀的制剂 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3659B1 (ar) * | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
IN2014CH00151A (zh) * | 2014-01-13 | 2015-07-17 | Hetero Research Foundation |
-
2016
- 2016-03-25 CN CN201610179590.8A patent/CN105726472B/zh active Active
- 2016-03-25 CN CN201911109940.3A patent/CN110772480B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10306724A1 (de) * | 2002-02-28 | 2003-09-18 | G O T Therapeutics Gmbh | Vesikuläre Verkapselung von Bendamustin |
CN101219112A (zh) * | 2008-01-28 | 2008-07-16 | 济南帅华医药科技有限公司 | 一种含苯达莫司汀的复方抗癌缓释注射剂 |
CN102164579A (zh) * | 2008-09-25 | 2011-08-24 | 赛福伦公司 | 苯达莫司汀的液体配制品 |
CN102413816A (zh) * | 2009-04-28 | 2012-04-11 | 赛福伦公司 | 苯达莫司汀的口服制剂 |
CN101584668A (zh) * | 2009-06-19 | 2009-11-25 | 江苏奥赛康药业有限公司 | 盐酸苯达莫司汀冻干粉针剂 |
CN104203235A (zh) * | 2012-02-14 | 2014-12-10 | 鹰制药股份有限公司 | 苯达莫司汀的制剂 |
CN104302291A (zh) * | 2012-03-20 | 2015-01-21 | 鹰制药股份有限公司 | 苯达莫司汀的制剂 |
CN103989641A (zh) * | 2014-05-29 | 2014-08-20 | 四川汇宇制药有限公司 | 一种注射用盐酸苯达莫司汀组合物的制备方法 |
Non-Patent Citations (2)
Title |
---|
BINA GIDWANI等: ""Formulation, characterization and evaluation of cyclodextrin-complexed bendamustine-encapsulated PLGA nanospheres for sustained delivery in cancer treatment"", 《PHARM DEV TECHNOL》 * |
POOJA DUBEY等: ""In vitro and in vivo evaluation of PEGylated nanoparticles of bendamustine for treatment of lung cancer"", 《ARTIFICIAL CELLS, NANOMEDICINE, AND BIOTECHNOLOGY》 * |
Also Published As
Publication number | Publication date |
---|---|
CN105726472A (zh) | 2016-07-06 |
CN110772480B (zh) | 2022-05-17 |
CN105726472B (zh) | 2019-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9597398B2 (en) | Formulations of bendamustine | |
JP6159567B2 (ja) | 既製のゲムシタビン注入溶液 | |
CN105726472B (zh) | 苯达莫司汀药剂组合物及应用 | |
US10632043B2 (en) | Premix formulation for parenteral use and packaging thereof | |
KR102656841B1 (ko) | 레파뮬린의 주사가능한 약제학적 제형 | |
RU2493824C2 (ru) | Концентрат эсмолола | |
CN1703209A (zh) | 通过静脉施用卤化挥发性麻醉药保护心脏和保护神经的方法 | |
US8426467B2 (en) | Colored esmolol concentrate | |
EP2846776B1 (en) | Parenteral esmolol formulation | |
US11642358B1 (en) | Stable pharmaceutical formulation | |
Ludwig | Parenteral dosage forms: introduction and historical perspective | |
KR20100022992A (ko) | 벤질 알코올을 갖는 다중 투여 농축 에스몰올 | |
US10117862B2 (en) | Remifentanil injection | |
US20230241218A1 (en) | Formulations of bendamustine | |
tcr Pharmacy | for Intrathecal William Stuart, RPh | |
EP2976063A1 (en) | Parenteral formulation of fluoroquinolone antibacterial agent and method for preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220425 Address after: 210000 Room 401, building E2, No. 9, Weidi Road, Xianlin University City, Xianlin street, Qixia District, Nanjing, Jiangsu Province Applicant after: Nanjing Baijin Enterprise Management Consulting Co.,Ltd. Address before: No.18, building 6928-210000, Xuanwu District, Nanjing City, Jiangsu Province Applicant before: NANJING KANGBOSI PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231101 Address after: Room 415, 4th Floor, No. 371 Taiping South Road, Qinhuai District, Nanjing City, Jiangsu Province, 210000 Patentee after: NANJING BAIXINYU MEDICINE Co.,Ltd. Address before: 210000 Room 401, building E2, No. 9, Weidi Road, Xianlin University City, Xianlin street, Qixia District, Nanjing, Jiangsu Province Patentee before: Nanjing Baijin Enterprise Management Consulting Co.,Ltd. |
|
TR01 | Transfer of patent right |